NSCLC: Zwei Positive Studien Zu PD-L1-Hemmer

Im Focus Onkologie
doi 10.1007/s15015-015-2129-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PD-L1-Hemmer Bei Vorbehandelten Patienten Mit NSCLC

Im Focus Onkologie
2017English

NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status

Pneumologie
MedicinePulmonaryRespiratory Medicine
2017English

MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pembro Ups Survival in PD-L1–positive HNSCC

Cancer Discovery
Oncology
2018English

Atezolizumab Combo Approved for PD-L1–positive TNBC

Cancer Discovery
Oncology
2019English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

Pneumologie
MedicinePulmonaryRespiratory Medicine
2018English

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy